Trial Profile

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of EDP-938 in Non-hospitalized Adults with Acute Respiratory Syncytial Virus Infection Who Are At High Risk for Complications

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 09 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Zelicapavir (Primary)
Indications Respiratory syncytial virus infections; Respiratory tract infections
Focus Therapeutic Use
Acronyms RSVHR
Sponsors Enanta Pharmaceuticals

01 Jul 2025 Status changed from active, no longer recruiting to completed.
05 Jun 2025 Status changed from recruiting to active, no longer recruiting.
12 May 2025 According to an Enanta Pharmaceuticals media release, trial met target enrollment of 180 participants for RSVHR and plan to complete enrollment in late May to capture the remainder of the current Northern Hemisphere RSV season. Company is on track to report topline data in late 3Q 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com